MyoGene Bio
PrivateLast Round
Seed
Nov 4, 2025
Total Funding Raised
$4.85M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
MyoGene Bio is a biotechnology company that develops gene-editing therapies for Duchenne muscular dystrophy and other muscle diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MyoGene Bio Comparables
Compare MyoGene Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Myosana Therapeutics | 81% | |
| AAVogen, Inc. | 80% | |
| ART BioScience | 78% |
MyoGene Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 4, 2025 | ||||
| VC Round | May 11, 2023 | ||||
| Grant | Dec 15, 2021 | ||||
| Grant | Dec 16, 2020 |
MyoGene Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CureDuchenne Ventures | VC Round |
| Parent Project Muscular Dystrophy | Seed |
| Duchenne UK | Seed |
| California Institute for Regenerative Medicine | Grant |
| How Women Invest | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 71% MoM, reaching 2K.
- Jun 19, 2026
Monthly visitors increased 66% MoM.
Recent news
Latest coverage and updates
- attends_eventAug 24, 2026
MyoGene Bio LLC will attend event TechCrunch Disrupt 2026 on Oct 13th '26.
MyoGene Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MyoGene Bio's valuation, stock price, and market status.
Is MyoGene Bio a public or private company?
MyoGene Bio is a private company.
What is the current stock price of MyoGene Bio?
MyoGene Bio is a private company with no public stock price. Caplight tracks MyoGene Bio's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is MyoGene Bio worth (valuation)?
Valuation information for MyoGene Bio is not publicly available.
Can I buy MyoGene Bio stock?
MyoGene Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MyoGene Bio's last funding round?
MyoGene Bio's most recent funding round was Seed on November 4, 2025.
Who are the main investors in MyoGene Bio?
Key investors in MyoGene Bio include CureDuchenne Ventures, Parent Project Muscular Dystrophy, Duchenne UK, California Institute for Regenerative Medicine, How Women Invest.
Will MyoGene Bio IPO soon?
No public IPO plans have been announced for MyoGene Bio.
How can I track MyoGene Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MyoGene Bio's secondary market activity and sign up for updates.